CSL Limited
2019 Half Year Results
13 February 2019
Paul Perreault, CEO and MD
David Lamont, CFO
Legal Notice

Forward looking statements
The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks
Except where otherwise noted, brand names designated by a ™ or © throughout this presentation are trademarks either owned by and/or licensed to CSL.
Delivering on Strategy

Growth

CSL Behring

• PRIVIGEN® sales +17%\(^1\)
• HIZENTRA® sales +14%\(^1\)
• IDELVION® sales +55%\(^1\)
• HAEGARDA® sales more than tripled
• KCENTRA® sales up 19%\(^1\)

Seqirus

• Influenza vaccine sales +23%\(^1\)
• Holly Springs – FCC 3.0 approved delivering future antigen capacity expansion
• FLUCELVAX® - compelling real world effectiveness data
• FLUAD® sales more than doubled
  – Record 9.8m doses in the UK

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.

Driven by Our Promise™
Delivering on Strategy

**Innovation**
- HIZENTRA® approved for CIDP in Australia
- 5 new products into human trials
- Recruitment for CSL 112 progressing well
- Transplant franchise continues to emerge

**Efficiency**
- New ERP systems
- New research facility in Melbourne
- Major capital projects progressing

**People & Culture**
- CSL named in Top 100 Global Diversity and Inclusion Index (Thomson Reuters)
- Top 50 companies for Diversity in the US (Forbes)
New Product Launches – CSL Behring

5 major launches in 24 months
Some of the most successful launches in the industry
Significant contribution to the business now…in future
# CSL Behring Sales 1H19

## Therapeutic Group

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Sales $m</th>
<th>% Change¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunoglobulins</td>
<td>1,708</td>
<td>12%</td>
</tr>
<tr>
<td>Haemophilia</td>
<td>536</td>
<td>(2%)</td>
</tr>
<tr>
<td>Albumin</td>
<td>420</td>
<td>(4%)</td>
</tr>
<tr>
<td>Specialty</td>
<td>803</td>
<td>13%</td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>3,468</strong></td>
<td><strong>8%</strong></td>
</tr>
</tbody>
</table>

¹. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.

---

1. **US$3.5b**
   - North America: 50%
   - EU: 28%
   - Asia Pac: 15%
   - ROW: 7%

- **Therapy Sales**
  - Immunoglobulins: 1,708 m, 12% change
  - Haemophilia: 536 m, (2%) change
  - Albumin: 420 m, (4%) change
  - Specialty: 803 m, 13% change
  - Other: 1 m

- **Total Sales**: 3,468 m, 8% change
Immunoglobulins

Substantial above market growth: sales up 12%¹

• 17% growth¹

• Increased diagnosis & awareness:
  - Primary Immune Deficiency
  - Secondary Immune Deficiency

• 14% growth¹

• Most used SCIG:
  - ~ 60% new starts
  - ~ 75% of patients naïve to IG

• Patient benefits:
  - Convenience of self administration
  - Lower adverse reactions

CIDP label claim approvals FY18:

• Early indicators for demand positive

CARIMUNE® phasing out

¹. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.
Haemophilia

Sales down 2%<sup>1</sup>

• Launched in 13 countries
• Exceptional growth +55%<sup>1</sup>
• Strong uptake in Japan
• Transformational product
• Achieving 60% of switches
• Over 1,100 patients

• Launched in 14 countries
• Accelerating adoption – over 500 patients
• AFSTYLA® expected to replace and expand on economic return previously derived from HELIXATE®

Plasma Coagulation Factors

• Manufacturing bottlenecks:
  - HUMATE® / BERIATE®
• MONONINE® to IDELVION® switches
• Tender volatility
• ASP mix shift

Recombinant Coags +9%<sup>1</sup>

PD Coags -11%<sup>1</sup>

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.
Albumin

Sales down 4%\(^1\)
Volume up 3%

Temporary constriction in import supply for China

China approval for Kankakee AlbuRx\(^\circledR\) pending

Strong growth in Europe and Emerging Markets

---

CSL’s new Good Supply Practices (GSP) license - China

Benefits – phasing in over the next 12 to 18 months

- Improved participation in value chain
- Removes reliance on 3rd parties
- CSL becomes a T1 distributor

---

\(^1\) Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.
Specialty Products

Sales up 13%¹

- Continued strong demand
  - Sales tripled
- >50% market share of US prophylaxis patients
- Attractive product profile continues to drive adherence and new patient starts

Global sales +19%¹
- US +23%¹
- Strong take up in Japan:
  - 800 hospitals
  - 2,800 patients

- Impacted by launch of HAEGARDA®

WOUND HEALING

- Sales normalised following atypical PCP
- Sales consistent with trailing period

¹. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.
Efficiency

New Research Facility

• State-of-the-art research facility opened in Melbourne

• $46 million facility expands the footprint of the Bio21 Institute by 5,000 square metres

• Research scientists at Bio21 to double from 75 to around 150 over time

New ERP Systems

• New ERP systems being implemented across CSL Behring & Seqirus

• US/EU rollout completed

• Asia Pacific rollout underway
Innovation
Future CSL Behring Therapeutic Area Framework

- Immunology and Neurology
- Haematology and Thrombosis
- Transplant
- Respiratory
- Cardiovascular and Metabolic

Plasma Fractionation
Recombinant Technology
Gene and Cell Therapy
Seqirus Revenue 1H19

**Category**

- **+21%**

<table>
<thead>
<tr>
<th>Category</th>
<th>1H18</th>
<th>1H19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluad</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pandemic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Region**

- **US$949m**
- North America 71%
- EU 14%
- Asia Pac 10%
- ROW 5%

Growth in QIV & FLUAD

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.

Driven by Our Promise™
Seqirus – Operating Highlights

- FCC3.0 approval, driving uplift in capacity at Holly Springs
- Real world effectiveness data: FLUCELVAX® more effective than standard egg-based QIV in preventing influenza-like illness in 2017/18 season in the US
- FLUAD® and FLUCELVAX® preferred recommendation for 65+ cohort in the UK
- Completed distribution of a record 9.8mds of FLUAD® in the UK
- AFLURIA® 6m+ age indication in US

Looking forward...

- SH 2019: FLUAD® preferred recommendation for 65yr+ in Australian public market
- NH 2019/20: Launch of FLUCELVAX TETRA® in EU
- New investment in Holly Springs fill and finish to meet growing cell-culture demand
- Liverpool fill & finish operational from SH 2021
Financials
David Lamont - CFO
Financial Highlights – NPAT

$1,086m
1H18

+7% REPORTED

$1,161m
1H19

$1,196m @CC

+10%¹

FX $35m

¹ Constant Currency (CC) removes the impact of exchange rate movements facilitating comparability of operational performance. See end note for further detail.
## Financial Highlights – CSL Group

<table>
<thead>
<tr>
<th>Half year ended Dec</th>
<th>1H18 Reported</th>
<th>1H19 Reported</th>
<th>1H19 at CC&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Change %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenue</td>
<td>4,147</td>
<td>4,505</td>
<td>4,581</td>
<td>11%&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>EBIT</td>
<td>1,476</td>
<td>1,553</td>
<td>1,566</td>
<td>6%&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>35.6%</td>
<td>34.5%</td>
<td>34.2%</td>
<td></td>
</tr>
<tr>
<td>NPAT</td>
<td>1,086</td>
<td>1,161</td>
<td>1,196</td>
<td>10%&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Cashflow from Operations</td>
<td>840</td>
<td>535</td>
<td></td>
<td>-36%</td>
</tr>
<tr>
<td>ROIC</td>
<td>32.8%</td>
<td>29.9%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS ($)</td>
<td>2.40</td>
<td>2.56</td>
<td>2.64</td>
<td>10%&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>DPS ($)</td>
<td>0.79</td>
<td>0.85&lt;sup&gt;#&lt;/sup&gt;</td>
<td></td>
<td>8%</td>
</tr>
</tbody>
</table>

<sup>1</sup> Constant Currency (CC) removes the impact of exchange rate movements facilitating comparability of operational performance. See end note for further detail.

<sup>#</sup> Converted to Australian currency, the interim dividend is approximately $1.20, up 20%.
CSL Group – Reported Expenses

**Investment in the future**

- R&D
- Employee growth
- Ongoing new product support
- Facilities expansion & New technology - D&A up 17%

**One-offs**

- World Federation of Hemophilia product donation
- FX – unfavourable $65 million

<table>
<thead>
<tr>
<th>Expense</th>
<th>1H19</th>
<th>Movement $M</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D</td>
<td>391</td>
<td>48</td>
<td>14</td>
</tr>
<tr>
<td>S&amp;M</td>
<td>423</td>
<td>69</td>
<td>19</td>
</tr>
<tr>
<td>G&amp;A</td>
<td>256</td>
<td>71</td>
<td>39</td>
</tr>
<tr>
<td>Finance</td>
<td>93</td>
<td>41</td>
<td>78</td>
</tr>
</tbody>
</table>
CSL Behring Margin

Full year margin more representative of performance

Modest increase in plasma costs tempering margin expansion

Uneven expenditure phasing 1H v 2H
## Key Capital Projects – Completion Timeline

<table>
<thead>
<tr>
<th>Technology</th>
<th>FY19</th>
<th>FY20</th>
<th>FY21</th>
<th>FY22</th>
<th>FY23</th>
<th>FY24</th>
<th>FY25</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERP Systems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterprise Process Management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Base Frac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kankakee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marburg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Broadmeadows</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Base Frac Modules</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finishing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bern IG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marburg Filling Plant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IG Modules</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Berinert / C1 Precipitate Capacity Increase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lengnau</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma Centres (continuous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSL 112</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seqirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fill &amp; Finish - Liverpool</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holly Springs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
China – GSP License

**Sales recognition – timing adjustment**

- Currently - sale to 3rd party distributor recognised ex-factory
- Transition in FY20:
  - Sale recognised when made to customer
  - Multi-month one-off sales timing adjustment in FY20
  - No impact on supply to patients
Outlook for FY19

- Business expectations 2H19:
  - Continued strong demand for CSL’s therapies
  - Expenditure phasing
  - Seqirus seasonality (loss making 2H)

Previous guidance
FY19 NPAT
~$1,880m to $1,950m

now guiding to around the upper end of range

1. For forward looking statements, refer to Legal Notice on page 2
2. Constant Currency (CC) removes the impact of exchange rates movements to facilitate comparability
3. Full year FX impact expected to be $60 million unfavourable assuming exchange rates remain steady for the remainder of the financial year
Financial Appendix
## CSL Behring Revenue

<table>
<thead>
<tr>
<th></th>
<th>1H18</th>
<th>1H19</th>
<th>1H19 CC</th>
<th>Change %&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunoglobulins</strong></td>
<td>1,558</td>
<td>1,708</td>
<td>1,746</td>
<td>12%</td>
</tr>
<tr>
<td>Albumin</td>
<td>452</td>
<td>420</td>
<td>433</td>
<td>(4%)</td>
</tr>
<tr>
<td><strong>Haemophilia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Recombinants</td>
<td>260</td>
<td>281</td>
<td>282</td>
<td>9%</td>
</tr>
<tr>
<td>- Plasma derived</td>
<td>297</td>
<td>255</td>
<td>264</td>
<td>(11%)</td>
</tr>
<tr>
<td><strong>Specialty</strong></td>
<td>717</td>
<td>803</td>
<td>810</td>
<td>13%</td>
</tr>
<tr>
<td>Other sales (mainly plasma)</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Total Product Sales</strong></td>
<td>3,288</td>
<td>3,468</td>
<td>3,536</td>
<td>8%</td>
</tr>
<tr>
<td>Other Income</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Royalties &amp; Licence Revenue</td>
<td>63</td>
<td>85</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>3,356</td>
<td>3,556</td>
<td>3,625</td>
<td>8%</td>
</tr>
</tbody>
</table>

<sup>1</sup> Constant Currency (CC) removes the impact of exchange rate movements facilitating comparability of operational performance. See end note for further detail.
## Seqirus Revenue

<table>
<thead>
<tr>
<th>Half year ended Dec US$ Millions</th>
<th>1H18</th>
<th>1H19</th>
<th>1H19 CC¹</th>
<th>Change %¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>QIV</td>
<td>306</td>
<td>419</td>
<td>419</td>
<td>37%</td>
</tr>
<tr>
<td>TIV</td>
<td>175</td>
<td>60</td>
<td>61</td>
<td>-65%</td>
</tr>
<tr>
<td>Adjuvanted</td>
<td>131</td>
<td>272</td>
<td>273</td>
<td>109%</td>
</tr>
<tr>
<td>Other / In-licence</td>
<td>99</td>
<td>123</td>
<td>128</td>
<td>30%</td>
</tr>
<tr>
<td><strong>Total Product Sales</strong></td>
<td>710</td>
<td>874</td>
<td>881</td>
<td>24%</td>
</tr>
<tr>
<td>Pandemic</td>
<td>60</td>
<td>65</td>
<td>67</td>
<td>11%</td>
</tr>
<tr>
<td>Other Income</td>
<td>21</td>
<td>9</td>
<td>9</td>
<td>-56%</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>791</td>
<td>949</td>
<td>957</td>
<td>21%</td>
</tr>
</tbody>
</table>

¹ Constant Currency (CC) removes the impact of exchange rate movements facilitating comparability of operational performance. See end note for further detail.

Seasonal Influenza vaccines +23%¹
Notes

(9) Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars, at the rates that were applicable to the prior comparable period (translation currency effect); b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior comparable period (transaction currency effect); and c) by adjusting for current year foreign currency gains and losses. The sum of translation currency effect, transaction currency effect and foreign currency gains and losses is the amount by which reported net profit is adjusted to calculate the operational result.

Summary NPAT
Reported net profit after tax $1,160.7m
Translation currency effect (a) $ (2.5m)
Transaction currency effect (b) $ 6.3m
Foreign Currency (gains) & losses (c) $ 31.5m
Constant currency net profit after tax * $1,196.0m

a) Translation Currency Effect $(2.5m)
Average Exchange rates used for calculation in major currencies (Six months to Dec 18/Dec 17) were as follows: USD/EUR (0.86/0.85); USD/CHF (0.99/0.97).

b) Transaction Currency Effect $6.3m
Transaction currency effect is calculated by reference to the applicable prior year exchange rates. The calculation takes into account the timing of sales both internally within the CSL Group (ie from a manufacturer to a distributor) and externally (ie to the final customer) and the relevant exchange rates applicable to each transaction.

c) Foreign Currency Loss $31.5m
Foreign currency gains recorded during the period.

Summary Sales
Reported sales $4,342.6m
Currency effect $ 74.5m
Constant currency sales* $ 4,417.1m

* Constant currency net profit after tax and constant currency sales have not been audited or reviewed in accordance with Australian Auditing Standards.
CSL Limited

Contact:
Mark Dehring
VP Investor Relations
📞 +61 3 9389 3407
✉️ mark.dehring@csl.com.au

Bernard Ronchi
Senior Manager, Investor Relations
📞 +61 3 9389 3470
✉️ bernard.ronchi@csl.com.au